Three start-ups are aiming to create gene-edited babies. Columnist Michael Le Page has no doubt that editing our offspring ...

This stock is a great choice for cautious and aggressive investors.

Get the latest Moderna (MRNA) stock analysis: balanced risk-reward, new vaccine launches, and pipeline insights. See why we ...

A Stanford-led study probes why a very small number of people develop heart inflammation shortly after mRNA COVID-19 ...

Non-profit arm of the de-extinction company secures an additional $50 million, expands global projects and partnerships, and releases its inaugural Impact Report detailing progress in the fight ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use has recommended granting marketing authorization for Moderna’s new RNA-based vaccine, mNexspike, for preventing ...

Shares of two major Covid-19 vaccine makers declined Monday after a Food and Drug Administration official claimed the shots led to 10 children’s deaths and said the agency would tighten ...

Moderna Inc. fell in trading Monday after the Food and Drug Administration said in a memo late last week it would place new restrictions on which vaccines hit the market. Vinay Prasad, a top FDA ...

Moderna Inc. shares rose after the company posted a narrower third-quarter loss than Wall Street expected, a sign that its cost-cutting measures are helping offset the decline of its Covid business.

Moderna MRNA-0.16%decrease; red down pointing triangle swung to a loss and logged lower sales in the third quarter as it works to expand its offerings amid weakening demand for its Covid-19 vaccine.